Colorectal Cancer Clinical Trial
Official title:
Comparison Between Faecal Occult Blood Test (FOBT), Computed Tomographic Colonography (CTC) With Computer Aided Diagnosis (CAD) and Colonoscopy as a Primary Screening Test for Colorectal Cancer. Validation of a Teleradiology Model. Biological Banking in Subjects Recruited for Colonoscopy or CTC.
RATIONALE: Computed tomographic colonography (CTC) has proven to be accurate in detecting
colorectal neoplasms and may be a primary test in colorectal cancer screening.
PURPOSE: This clinical trial will compare participation rate, diagnostic yield and costs of
computed tomographic colonography, faecal occult blood test (FOBT) and colonoscopy (CO) as a
primary screening test in a population-based programme.
OBJECTIVES:
Primary objectives:
- To compare the participation rate to faecal occult blood test (FOBT), computed
tomographic colonography (CTC) and colonoscopy (CO) as a primary screening test in a
population-based programme for colorectal cancer.
- To compare the participation rate to CTC with reduced cathartic preparation versus CTC
with standard bowel preparation.
- To compare the detection rate for cancer or advanced adenomas of CTC with computer aided
diagnosis (CAD) versus three rounds of FOBT every second year.
- To evaluate referral rate for colonoscopy induced by primary CTC versus three rounds of
FOBT every second year.
- To compare costs of the three screening strategies.
Secondary objectives:
- To compare the expected and perceived discomfort of colonoscopy and computed tomographic
colonography as assessed with a structured questionnaire.
- To evaluate the rate of complications in each group.
- To validate a teleradiology model for computed tomographic colonography.
- To create a biological bank of blood and stool specimens from subjects who undergo
computed tomographic colonography, primary colonoscopy and second level colonoscopy.
DESIGN:
14,000 subjects aged 55-64 years, living in the Florence District and never screened for
colorectal cancer, will be randomized in 3 arms:
- group 1 (5,000 persons) invited to CTC (divided into: subgroup 1A with reduced cathartic
preparation and subgroup 1B with standard bowel preparation);
- group 2 (8,000 persons) invited to biannual FOBT for 3 rounds;
- group 3 (1,000 persons) invited to CO.
Subjects of each group will be invited by mail to undergo the selected test. Individuals of
each group will receive an invitation letter and an information leaflet, containing
information about colorectal cancer, importance of screening, and advantages and possible
risks of the selected test.
Invitation letter for the FOBT group contains instructions on how to pick-up the kit test at
the nearest pharmacy. The FOBT screening test adopted is OC-SENSOR DIANA (Eiken Chemical Co.,
Tokyo, Japan), a quantitative, completely automated immunochemical test, based on latex
agglutination. Positivity threshold is set at 100 ng/ml of sample solution. Invited subjects
are asked to collect a single sample of faeces, without dietary restrictions. Sample are
retuned according to the routine procedure of Florence screening programme.
Invitation letter for CTC and colonoscopy contains a phone number and an email address of the
screening centre. All invitees have the option to call or send an email to the screening
centre in order to receive an appointment for a prior consultation. All non-responders will
receive a remainder by mail after three months. Non-responders to reminder will be invited to
FOBT according with current screening procedure.
Subjects who accept invitation for CTC or CO will have a consultation at the screening centre
with a trained nurse. During the consultation subjects will be informed about the study
protocol, the screening examination to which they are invited, the bowel preparation, and the
management in case of positive results. All subjects tested positive to FOBT or CTC (mass or
at least one polyp ≥ 6 mm) will be invited to undergo total colonoscopy. Then, subjects will
be scheduled for the selected examination (CTC or CO).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |